[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@watermedhenry Henry LEUNG
Henry LEUNG posts on X about $alks, $krys, away from, $jnj the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXX +685%
- X Month XXXXX +4.30%
- X Months XXXXXX -XX%
- X Year XXXXXXX +309%
Mentions: X #
- X Month X -XX%
- X Months XX -XX%
- X Year XX -XX%
Followers: XXX #
- X Week XXX -XXXX%
- X Month XXX -XXXX%
- X Months XXX +18%
- X Year XXX +7.40%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks finance
Social topic influence $alks #1, $krys #4, away from, $jnj, $biib, over the, $avdls, 6 months
Top assets mentioned Alkermes Inc. plc (ALKS) Krystal Biotech, Inc. Common Stock (KRYS) Johnson & Johnson (JNJ) Biogen Inc (BIIB)
Top Social Posts #
Top posts by engagements in the last XX hours
"$ALKS more impressions: Company is likely moving focus away from partnership products.as there is no specific full-year guidance for revenue from those products in FY23A result. It is understandable that INVEGA (with $JNJ for schizophrenia) and VUMERITY (with $BIIB for multiple sclerosis) like have tough fights in the presence of COBENFY (at least no black box warning like INVEGA) and OCREVUS (considered as high-efficacy treatment in an article by Archit B Baskaran et al. while VUMERITY as moderate one). $ALKS proprietary products come with some optimizations compared with old products"
X Link @watermedhenry 2025-10-16T07:50Z XXX followers, XXX engagements
"$KRYS platform tech designation for KB801: After likely failure/deprioritization of KB707 for sure it raises question over the sustainability and development of its HSV-1 platform. The FDA designation boosts confidence in $KRYS platform to deliver harvest besides COL7A1. I'm not sure if $KRYS can meet the timeline sharing KB801 Ph1/2 data expected in 2H25E which likely by end of 2025 as the 1st patient dosed in early July and interim analysis at week 9"
X Link @watermedhenry 2025-10-15T03:30Z XXX followers, XXX engagements
"$ALKS impression: Company shares has recovered from drawback of orexin X receptor agonist Alixorexton's Vibrance-1 Ph2 data suggesting it didn't achieve statistical significance at 4mg and 8mg vs placebo. However it would likely improve through increasing sample size. Referring to $AVDL's LUMRYZ Ph3 data the SD of effective experimental group was less than such in placebo group which is also applicable to the $ALKS Alixorexton 6mg a less range compared to non-statistical significant groups 4mg and 8mg. $ALKS is an interesting Company which its CEO Richard Pops was at the same position in 1991"
X Link @watermedhenry 2025-10-15T08:04Z XXX followers, XXX engagements
"$KRYS label expansion of VYJUVEK: VYJUVEK label expansion includes pediatric patients from birth and before the expansion it was since X months old. Looks like meaningful as DEB onset would be upon birth. Also label expansion including home setting by patient would be convenient"
X Link @watermedhenry 2025-09-16T03:01Z XXX followers, XXX engagements